Our previous blog post covered the EU Commission’s (“EC”) Temporary Framework of 19 March 2020 (“Temporary Framework”), which aims at enabling national governments to use the full flexibility of…
Common ownership currently is one of the focus topics in the antitrust community. Einer Elhauge, a Harvard Law professor, has called it the “greatest anticompetitive threat of our times”. Others…
It has been just over a year since I last wrote on EU Merger Control and the Innovation Theory of Harm (the ITOH), see here.
And what a year it has been. We still have no real idea what Brexit means…
‘Product hopping’, or ‘evergreening’, are expressions used (by antitrust authorities and industry respectively) to describe strategies employed by pharmaceutical companies to protect sales of a…
As 2018 and Father Christmas approach, it is important to remember that there will be those in Copenhagen next month more interested in dominant market presence than Christmas market presents. To the…
Complex transactions are subject to an increased level of antitrust scrutiny by competition authorities. This often results in extended waiting periods between signing and closing – it can nowadays…
In the European Union, Big Pharma has been operating with a target on its back for the best part of the last decade. Eight years after the conclusion of the 2008 pharmaceutical sector inquiry, it is…
We live in a rapidly changing world. The monikers of change are well known to all of us.
Trump. Brexit. Eddie Jones.
The future is unpredictable. As Joe Cocker sang, "who knows what tomorrow brings…
Recent months have seen a surge of new initiatives by European antitrust enforcers applying competition law rules to holders and processors of “big data.” Big data often is described as the…
We have recently celebrated the 25th anniversary of the EU Merger Regulation, which came into force on 21 September 1990.
Since that date, we have seen an exponential growth in merger control…
